WallStreetZenWallStreetZen

NASDAQ: PYPD
Polypid Ltd Stock

Overview
ForecastEarningsRevenueDividendOwnership
$3.37-0.06 (-1.75%)
Updated Sep 17, 2025
PYPD Price
$3.37
Fair Value Price
$1.02
Market Cap
$52.75M
52 Week Low
$2.30
52 Week High
$3.93
P/E
0.37x
P/B
2.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$34.53M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.84
Operating Cash Flow
-$26M
Beta
0.68
Next Earnings
Nov 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

PYPD Overview

PolyPid LTD. is developing products based on a polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs and improve surgical results. The company's lead product candidate is D-PLEX100, to prevent sternal (bone) and abdominal (soft tissue) surgical site infections. PolyPid was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine PYPD's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
PYPD
Ranked#258 of 479

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Theravance Biopharma (TBPH)
$14.05A
Biocryst Pharmaceuticals (BCRX)
$7.70A
Rigel Pharmaceuticals (RIGL)
$34.22A
View Top Biotech Stocks

Be the first to know about important PYPD news, forecast changes, insider trades & much more!

PYPD News

Overview

Due Diligence Score

–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PYPD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PYPD ($3.37) is overvalued by 230.78% relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PYPD ($3.37) is not significantly undervalued (230.78%) relative to our estimate of its Fair Value price of $1.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PYPD was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PYPD due diligence checks available for Premium users.

Valuation

PYPD fair value

Fair Value of PYPD stock based on Discounted Cash Flow (DCF)

Price
$3.37
Fair Value
$1.02
Overvalued by
230.78%
PYPD ($3.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PYPD ($3.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PYPD was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PYPD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0.37x
Industry
-97.28x
Market
37.36x
PYPD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PYPD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

PYPD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.58x
Industry
4.69x
PYPD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PYPD's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.0M
Profit Margin
0%
PYPD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$37.7M
Liabilities
$17.2M
Debt to equity
0.84
PYPD's short-term assets ($29.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PYPD's short-term assets ($29.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PYPD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PYPD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
PYPD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PYPD vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
PYPDD$52.75M-1.75%0.37x2.58x
KPTIF$52.72M-2.88%-0.41x-0.22x
CAMP–$52.22M-6.50%0.06x1.31x
JUNSC$51.90M-0.67%-7.84x38.73x
PDSBD$53.63M-4.17%-1.25x3.36x
View Top Biotech Stocks

Polypid Stock FAQ

What is Polypid's quote symbol?

(NASDAQ: PYPD) Polypid trades on the NASDAQ under the ticker symbol PYPD. Polypid stock quotes can also be displayed as NASDAQ: PYPD.

If you're new to stock investing, here's how to buy Polypid stock.

What is the 52 week high and low for Polypid (NASDAQ: PYPD)?

(NASDAQ: PYPD) Polypid's 52-week high was $3.93, and its 52-week low was $2.30. It is currently -14.25% from its 52-week high and 46.52% from its 52-week low.

How much is Polypid stock worth today?

(NASDAQ: PYPD) Polypid currently has 15,654,129 outstanding shares. With Polypid stock trading at $3.37 per share, the total value of Polypid stock (market capitalization) is $52.75M.

Polypid stock was originally listed at a price of $570.00 in Jun 26, 2020. If you had invested in Polypid stock at $570.00, your return over the last 5 years would have been -99.41%, for an annualized return of -64.16% (not including any dividends or dividend reinvestments).

How much is Polypid's stock price per share?

(NASDAQ: PYPD) Polypid stock price per share is $3.37 today (as of Sep 17, 2025).

What is Polypid's Market Cap?

(NASDAQ: PYPD) Polypid's market cap is $52.75M, as of Sep 18, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Polypid's market cap is calculated by multiplying PYPD's current stock price of $3.37 by PYPD's total outstanding shares of 15,654,129.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.